{"filing":{"accession_number":"0001628280-26-047584","cik":"0001636651","ticker":"OVID","company_name":"Ovid Therapeutics Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"ovid-20260707.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/ovid-20260707.htm"},"events":[{"id":16589,"run_id":14820,"accession_number":"0001628280-26-047584","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both the departure of Jeffrey Rona as Chief Business and Financial Officer and the appointment of Charles Carter as Chief Financial Officer, effective July 6, 2026. While both events occur, the principal disclosed action centers on Carter's appointment to the CFO role with detailed compensation arrangements (base salary of $460,000, 35% bonus target, 50,000 RSU grant), making exec_appointment the most salient classification. The departure is secondary context to the succession event.","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14735,"accession_number":"0001628280-26-047584","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of Jeffrey Rona as Chief Business and Financial Officer and the appointment of Charles Carter as Chief Financial Officer, effective July 6, 2026. While both events occur, the principal disclosed action centers on Carter's appointment to the CFO role with detailed compensation arrangements (base salary of $460,000, 35% bonus target, 50,000 RSU grant), making exec_appointment the most salient classification. The departure is secondary context to the succession event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:04:37.234273+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14735,"accession_number":"0001628280-26-047584","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of Jeffrey Rona as Chief Business and Financial Officer and the appointment of Charles Carter as Chief Financial Officer, effective July 6, 2026. While both events occur, the principal disclosed action centers on Carter's appointment to the CFO role with detailed compensation arrangements (base salary of $460,000, 35% bonus target, 50,000 RSU grant), making exec_appointment the most salient classification. The departure is secondary context to the succession event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T11:04:37.234273+00:00","company_name":"Ovid Therapeutics Inc.","ticker":"OVID","filing_date":"2026-07-08"}]}